axinn

Axinn Team Prevails for Alvogen in Suboxone Antitrust Litigation

NEWS | LESS THAN 1 MIN READ

August 26, 2020

In another victory on behalf of Axinn's client Alvogen, a district court affirmed a previous court ruling that both Alvogen and Dr. Reddy's Laboratories can move forward with antitrust counterclaims against Indivior. The counterclaims arise from a dispute over generic versions of Suboxone, Indivior's opioid addiction treatment. The Axinn team included Matt Becker and Ted Mathias.

Related People



Matthew J. Becker



Ted Mathias

Related Services

Antitrust

To subscribe to our publications, click here.

Featured Insights

- GCR Live: Law Leaders Europe 2025
 SPEAKING ENGAGEMENT ANTITRUST
- AHLA Annual Meeting 2025
 SPEAKING ENGAGEMENT ANTITRUST
- SABA North America Annual Conference 2025
 SPEAKING ENGAGEMENT ANTITRUST
- Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
 WEBINAR ANTITRUST
- Volunteer Lawyers for the Arts Champions of the Arts Awards and Gala 2025
 sponsorship ANTITRUST
- NJSBA Annual Meeting and Convention 2025
 SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- Cost-Effective and Efficient IP Litigation Strategies Making Paragraph IV Litigation Work for You
 WEBINAR INTELLECTUAL PROPERTY
- Hartford HealthCare Black and Red Gala 2025
 sponsorship ANTITRUST
- Informa CompLaw Antitrust West Coast Conference 2025
 SPEAKING ENGAGEMENT ANTITRUST

Recent Decision Shows the Heavy Burden of Actual Malice in Defamation Suits
 AXINN VIEWPOINTS LITIGATION & TRIALS

@ 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved